Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on April 1, 2025
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Tenth Consecutive Year
GlobeNewswire
·
April 1, 2025
MISSISSAUGA, Ontario, April 01, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that FeraMAX® is the #1 recommended iron supplement brand in Canada, based on a national survey of Canadian pharmacists and …
Merus nimmt an Kamingespräch auf der 24. jährlichen Needham Virtual Healthcare Conference teil
GlobeNewswire
·
April 1, 2025
UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), ein Unternehmen für klinische Onkologie, das innovative, multispezifische Antikörper in voller Länge und Antikörper-Wirkstoff-Konjugate ( …
Merus participera à une discussion informelle lors de la 24e conférence annuelle Needham Virtual Healthcare
GlobeNewswire
·
April 1, 2025
UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachussets, 01 avr. 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), entreprise spécialisée en oncologie développant des anticorps de pleine longueur multispécifiques et des conjugués anticorps-médicament …
Advanced Medical Balloons presents results from HYDRA-PMCF study of hygh-tec®, demonstrating high performance and safety
GlobeNewswire
·
April 1, 2025
HYDRA-PMCF-study evaluated hygh-tec®, a new polyurethane fecal management system hygh-tec® showed a high level of sealing performance (no leakage in 89.3%) and was safe to use (94.2% no signs of infection; GLOBIAD score = 0+1A) Full results will be …
Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit
GlobeNewswire
·
April 1, 2025
BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that updated results from its …
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
BRISBANE, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will …
Nitrase Therapeutics Presents Preclinical Data from Multiple Studies Demonstrating Its Antibody Prevents Pathological Spread of Parkinson’s Disease in an Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference
GlobeNewswire
·
April 1, 2025
- NDC-0524 is a First-in-class Monoclonal Antibody with High Selectivity for Nitrated Alpha-synuclein (nSyn) and is Expected to Begin a Randomized Phase 1/2a Trial in the Fourth Quarter of 2025 - Elevated nSyn is Found in Patients with Parkinson’s Disease, …
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, …
Avalyn Completes Successful Phase 1 Clinical Trials of AP02, its Novel Inhaled Formulation of Nintedanib, Preparing for Phase 2 Development in Idiopathic Pulmonary Fibrosis
GlobeNewswire
·
April 1, 2025
Topline data from the single- and multiple-ascending dose studies confirmed safety and favorable tolerability profile of AP02 at all dose levels Full safety, tolerability, and pharmacokinetics data to be presented at the American Thoracic Society 2025 …
RESTEM to Participate in Jones Las Vegas Technology and Innovation Conference
GlobeNewswire
·
April 1, 2025
MIAMI, April 01, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced its participation in the Jones Las Vegas …
Lantern Taps Industry Veteran for Labor, Union & Trust
GlobeNewswire
·
April 1, 2025
DALLAS, April 01, 2025 (GLOBE NEWSWIRE) -- Lantern, the Specialty Care Platform connecting 6 million members with the best surgery, cancer and infusions care, has named Lindsay Leeder, MSN, ARNP as Senior Vice President of Labor, Union …
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
April 1, 2025
CHARLESTOWN, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 43,374 restricted …
Scientific Industries to Host Fiscal Year 2024 Financial Results Investor Call on April 1, 2025
GlobeNewswire
·
April 1, 2025
BOHEMIA, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- Scientific Industries, Inc. (OTCQB: SCND), a life sciences tool provider, and a developer of digitally simplified bioprocessing products, announced it filed the Form 10K and issued a press release on March …
Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme
GlobeNewswire
·
April 1, 2025
CARLSBAD, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today they have entered a non-binding Memorandum of Understanding (MOU) to acquire Marizyme (OTC: MRZM). Qualigen and Marizyme have …
Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 Diabetes
GlobeNewswire
·
April 1, 2025
DSMB supports advancement for Sernova’s clinical trial Study is on track to meet key clinical trial endpoints LONDON, Ontario and BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading …
NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer’s Disease and Reinforcing Platform’s Strength Across Neurological Disorders
GlobeNewswire
·
April 1, 2025
BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer’s disease, and a …
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities
GlobeNewswire
·
April 1, 2025
RADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has released a new version of the Simcyp™ Simulator for physiologically-based pharmacokinetic (PBPK) modeling. Simcyp PBPK …
Study Finds Brain Training Also Helps Caregivers of Dementia Patients
GlobeNewswire
·
April 1, 2025
SAN FRANCISCO, April 01, 2025 (GLOBE NEWSWIRE) -- While a particular brain training app —BrainHQ from Posit Science — has already been shown to prevent cognitive decline and improve brain health in older adults, researchers at the University of Rochester …
Evaxion announces business update and full year 2024 financial results
GlobeNewswire
·
April 1, 2025
COPENHAGEN, Denmark, April 1, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces full year 2024 financial results. …
Context Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
·
April 1, 2025
PHILADELPHIA, April 01, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its …